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Comparison of Pregnancy Complication Rates: Does Opioid Agonist
Pharmacotherapy Make A Difference?
Abstract
Background: Over the past decade, the prevalence of opioid use disorder (OUD) in pregnant patients has
increased by 131% with an associated increase in pregnancy complications. Opioid agonist
pharmacotherapy (OAP) with methadone or buprenorphine is recommended by ACOG for the
management of OUD. The objectives of our study are to compare the incidence of pregnancy
complications among patients who at the time of their delivery used OAP, OAP plus any additional
substance (OAP+), illicit or prescribed opioids, and no opioids.
Methods: We conducted a retrospective cohort study at Berkshire Medical Center in Pittsfield, MA,
between January 1, 2018, through December 31, 2020, to compare the incidence of nine pregnancy
complications in patients who at the time of their delivery were using OAP, OAP+, illicit or prescribed
opioids, and no opioids. The data was analyzed with Chi-squared tests and a Bonferroni correction of the
p-value was used to adjust for comparison of the rates. The significance level used was p ≤ 0.025.
Results: There were 1979 deliveries during the 3-year study period with a total complication incidence of
23%. The complication incidence was 11% for OAP, 15% for OAP+, 42% for illicit or prescribed opioids, and
24% for no opioids. The incidence of complications in the OAP group was significantly lower than the
incidence in the no opioids group (11% vs 24%, p = 0.01). There was no significant difference in the
comparisons between other groups.
Discussion: Our study investigated nine pregnancy complications; no other single study included all of
these complications. Patients who used OAP had a significantly lower incidence of pregnancy
complications compared to those who used no opioids. A multisite cohort study showed a low incidence
of placental abruption in patients using methadone (3%), which was a similar outcome to the MOTHER
study (2.3%) and our study (1.4%). The results of this research could assist providers in counseling their
patients on the use of OAP in pregnancy.
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Abstract
Background: Over the past decade, the prevalence of opioid use disorder (OUD) in pregnant patients has increased by
131% with an associated increase in pregnancy complications. Opioid agonist pharmacotherapy (OAP) with methadone
or buprenorphine is recommended by ACOG for the management of OUD. The objectives of our study are to compare
the incidence of pregnancy complications among patients who at the time of their delivery used OAP, OAP plus any
additional substance (OAPþ), illicit or prescribed opioids, and no opioids.
Methods: We conducted a retrospective cohort study at Berkshire Medical Center in Pittsﬁeld, MA, between January 1,
2018, through December 31, 2020, to compare the incidence of nine pregnancy complications in patients who at the time
of their delivery were using OAP, OAPþ, illicit or prescribed opioids, and no opioids. The data was analyzed with Chisquared tests and a Bonferroni correction of the p-value was used to adjust for comparison of the rates. The signiﬁcance
level used was p ≤ 0.025.
Results: There were 1979 deliveries during the 3-year study period with a total complication incidence of 23%. The
complication incidence was 11% for OAP, 15% for OAPþ, 42% for illicit or prescribed opioids, and 24% for no opioids.
The incidence of complications in the OAP group was signiﬁcantly lower than the incidence in the no opioids group
(11% vs 24%, p ¼ 0.01). There was no signiﬁcant difference in the comparisons between other groups.
Discussion: Our study investigated nine pregnancy complications; no other single study included all of these complications. Patients who used OAP had a signiﬁcantly lower incidence of pregnancy complications compared to those
who used no opioids. A multisite cohort study showed a low incidence of placental abruption in patients using
methadone (3%), which was a similar outcome to the MOTHER study (2.3%) and our study (1.4%). The results of this
research could assist providers in counseling their patients on the use of OAP in pregnancy.
Keywords: Pregnancy complications, Opioid agonist pharmacotherapy, Methadone, Buprenorphine, Opioid use disorder

1. Introduction

T

he opioid crisis is a growing public health
issue in the United States. Over the past
decade, there has been a 131% increase in the
number of pregnant patients with opioid use disorder (OUD) documented at the time of delivery,
with an associated increase in pregnancy complications1. Opioid use in pregnancy can increase the
patient's risk of cardiac arrest, placental abruption,
preterm labor, oligohydramnios, blood transfusion,

premature rupture of membranes, cesarean delivery, and death2.
Opioid agonist pharmacotherapy (OAP) with
methadone or buprenorphine is recommended by
the American College of Obstetrics and Gynecology
for the management of pregnant patients with OUD.
The DSM-5 outlines 11 symptoms of OUD, two of
which must be present to make the diagnosis. These
symptoms include taking large amounts of opioids
over a longer period than intended, and a persistent
desire or unsuccessful efforts to cut down or control
opioid use. Literature on OAP primarily highlights
neonatal outcomes rather than pregnancy
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complications affecting the morbidity of the birthing
person3,4. Neonatal complications have been well
documented, especially for methadone use,
including increased risk of preterm birth, small for
gestational age, congenital anomalies, and neonatal
abstinence syndrome (NAS)5,6.Data broadly supports that the use of buprenorphine results in
decreased NAS severity and risk of preterm birth7,8.
There may be an increased risk of antenatal
bleeding for pregnant patients who use OAP,
including placental abruption and placenta previa,
as shown by two Canadian studies9,10.
Whether OAP use in pregnancy increases the risk
of other obstetrical complications, such as gestational
hypertension, pre-eclampsia, eclampsia, gestational
diabetes mellitus, and postpartum hemorrhage remains to be clariﬁed11,12. There is evidence that indicates pregnant patients prescribed methadone or
buprenorphine have a greater incidence of delayed
villous maturation, a larger placental size, and a
decreased fetoplacental weight ratio compared to a
control group13. Placental growth hormone is a
contributing factor to insulin resistance and resultant
gestational diabetes mellitus14. Hypertensive disorders and diabetes mellitus during pregnancy can
affect the development of the placenta, which can
lead to placental abruption15. The effects of OAP on
the pathophysiology of these conditions outside of
pregnancy have been reported in some animal
studies. A study by Sadava et al. reveals a correlation
between diabetes and methadone16. A physiologic
explanation for this ﬁnding may be that beta-endorphins stimulate glucagon secretion in the absence of
accompanying insulin secretion, which could
contribute to hyperglycemia17. Both methadone and
buprenorphine have been shown to be associated
with improved nutrition and access to prenatal care,
prevention of relapse, limitation of withdrawal
symptoms, and reduction of infection compared to
untreated OUD18,19.
It is important to understand the risks and beneﬁts of OAP during pregnancy to provide patients
with data to make informed decisions. Our

objectives were to compare the incidence of pregnancy complications among the four groups: patients who at the time of their delivery used OAP,
OAP plus any additional substance (OAPþ), illicit or
prescribed opioids, and those who did not use any
opioids (no opioids). Our primary hypothesis was
that the incidence of pregnancy complications
among patients who at the time of their delivery
were using OAP compared to those who used no
opioids would be similar. Our secondary hypothesis
was that the incidence of pregnancy complications
in patients who used OAPþ and those who used
illicit or prescribed opioids would be increased
compared to the other groups. The results of this
research may help providers in counseling their
patients who are considering starting or maintaining OAP during pregnancy, and update evidencebased best practices and guidelines.

2. Methods
We conducted a retrospective cohort study at
Berkshire Medical Center (BMC) in Pittsﬁeld, MA,
to compare the incidence of nine pregnancy complications in patients who at the time of their delivery were using OAP, OAPþ, illicit or prescribed
opioids, and no opioids (Table 1). Our study looked
at the records from all pregnant patients who
delivered at BMC from January 1, 2018, through
December 31, 2020. Inclusion criteria were all patients who delivered at BMC during the three-year
study period. Exclusion criteria were pregnant patients who chose pregnancy termination options
and those who were transferred to another hospital
prior to delivery. IRB exemption was obtained.
Data was obtained from BMC Medical Records
Department using ICD-10 codes to identify pregnant patients during the three-year study period
who were using opioids at the time of delivery. The
coding did not differentiate the types of opioids that
were used. We reviewed the records of each patient
to determine whether the patient was using OAP
versus illicit or prescribed opioids. We documented
any other substance use recorded at the time of

Table 1. Cohorts organized by opioid use status at the time of delivery
OAP
OAPþ

Illicit or prescribed opioids

No opioids

Methadone or buprenorphine
OAP plus any additional illicit or recreational substance that may be detected on a urine
toxicology screen such as amphetamines/methamphetamines, barbiturates, benzodiazepines,
cannabinoids, cocaine, and opiates
Morphine, hydromorphone, codeine, hydrocodone, oxycodone, fentanyl, carfentanil,
meperidine, tramadol, and heroin; does not include patients who received opioids only
as part of an epidural procedure
No recorded opioid use and those who ceased use in the ﬁrst trimester of pregnancy;
patients who received opioids as part of an epidural procedure are included in this group
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delivery, such as amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and illicit opiates. The total number
of deliveries by pregnant patients using OAP,
OAPþ, illicit or prescribed opioids, and no opioids
was determined.
All patients with pregnancy complications over
the study period were identiﬁed by BMC Medical
Records Department using ICD-10 codes for
placental abnormalities, hypertensive disorders,
and other speciﬁed complications. Placental abnormalities were deﬁned as placental abruption,
placenta accreta, placenta percreta, and placenta
increta. Hypertensive disorders were deﬁned as
gestational hypertension (GH), pre-eclampsia, and
eclampsia. Other complications included gestational diabetes mellitus (GDM) and postpartum
hemorrhage (PPH) (Table 2). We reviewed the records of all patients who had these pregnancy
complications and documented those who at the
time of delivery were using OAP, OAPþ, illicit or
prescribed opioids, and those who did not use any

opioids (Fig. 1). The data was extracted from records and de-identiﬁed.
We calculated and compared the incidence of
placental abnormalities, hypertensive disorders,
and other complications at the time of delivery in
each cohort. The data was analyzed with Chisquared tests to determine if there was a signiﬁcant
difference in the incidence of pregnancy complications. A Chi-squared test is used for categorical data
to determine whether there is a statistically signiﬁcant difference between the expected results and the
observed results. A Bonferroni correction of the pvalue was used to adjust for the comparison of two
rates against each other. The signiﬁcance level used
was p  0.025.

3. Results
There were 1979 deliveries at BMC over the threeyear study period. Of these, there were 72 deliveries
with pregnant patients who used OAP only, 42 used
OAPþ, 12 used illicit or prescribed opioids, and 1854
used no opioids (Table 3). There were 460

Table 2. Pregnancy complication categories
Placental abnormalities
Hypertensive disorders
Other complications

Placental abruption, placenta accreta, placenta percreta, placenta increta
Gestational hypertension (GH), pre-eclampsia, eclampsia
Gestational diabetes mellitus (GDM), postpartum hemorrhage (PPH)

All pregnant
patients who
delivered at BMC

OAP

OAP+

Illicit/prescribed
opioids

No opioids

Placental
abnormalities

Placental
abnormalities

Placental
abnormalities

Placental
abnormalities

Hypertensive
disorders

Hypertensive
disorders

Hypertensive
disorders

Hypertensive
disorders

Other
complications

Other
complications

Other
complications

Other
complications

Fig. 1. Approach to data collection.
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Table 3. Incidence of pregnancy complications in each cohort
Deliveries

Pregnancy Complications

Incidence

OAP
OAPþ
Illicit or Prescribed Opioids
No Opioids
Total

72
41
12
1854
1979

8
6
5
441
460

0.11
0.15
0.42
0.24
0.23

Incidence of Pregnancy Complications

Cohort

45.00%

(11%)
(15%)
(42%)
(24%)
(23%)

42%

40.00%
35.00%
30.00%
24%

25.00%
20.00%
15.00%

15%
11%

10.00%
5.00%
0.00%
OAP (n=72)

OAP+ (n=41)

Illicit/Prescribed
Opioids (n=12)

No Opioids
(n=1854)

Fig. 2. Incidence of pregnancy complications in each cohort.

pregnancy complications that met the inclusion
criteria, resulting in a total complication incidence of
23%. There were 8 complications for OAP only, 6 for
OAPþ, 5 for illicit or prescribed opioids, and 441
complications for no opioids (Table 3).
Of the total pregnancy complications, there were
16 placental abnormalities, 243 hypertensive disorders, and 201 other speciﬁed complications (Table
4). In the OAP group, there was 1 placental abnormality, 6 hypertensive disorders, and 1 other
complication. In the OAP þ group, there was 1
placental abnormality, 4 hypertensive disorders,
and 1 other complication. In the illicit or prescribed
opioids group, there were 2 placental abnormalities,
2 hypertensive disorders, and 1 other complication.
In the no opioids group, there were 12 placental
abnormalities, 231 hypertensive disorders, and 198
other complications (Table 4).
The total incidence of pregnancy complications
over the three-year study period was 23% (n ¼ 1979)
(Table 3). For each individual cohort, the incidence
was 11% for OAP (n ¼ 72), 15% for OAPþ (n ¼ 41),
42% for illicit or prescribed opioids (n ¼ 12), and
24% for no opioids (n ¼ 1854) (Table 3, Fig. 2).
The incidence of pregnancy complications in the
OAP group was signiﬁcantly lower than the
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incidence of pregnancy complications in the no
opioids group (11% vs 24%, p ¼ 0.01). There was no
signiﬁcant difference between OAP þ vs. OAP
(p ¼ 0.58), illicit or prescribed opioids vs. OAP
(p ¼ 0.14), OAP þ vs. illicit or prescribed opioids
(p ¼ 0.95), OAP þ vs. no opioids (p ¼ 0.17), and illicit
or prescribed opioids vs. no opioids (p ¼ 0.15)
(Table 5).

4. Discussion
The incidence of pregnancy complications among
patients who at the time of their delivery used OAP,
OAPþ, illicit or prescribed opioids, and no opioids
was investigated in this study. A total of 1979 deliveries were included and divided into each cohort,
and the incidence of pregnancy complications in
each group was determined. The results demonstrated a signiﬁcantly lower incidence of pregnancy
complications in the OAP group compared to the no
opioids group.
We primarily hypothesized that the incidence of
pregnancy complications among patients who were
using OAP compared to those who used no opioids
would be similar. This hypothesis was rejected
because we found a statistically signiﬁcant
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difference between these groups. Patients who used
OAP had a lower incidence of pregnancy complications than patients who used no opioids (11% vs
24%, p ¼ 0.01). This may be suggestive that OAP is
not worse than taking no opioids during pregnancy.
Reasons for this ﬁnding could include increased
medication monitoring and more frequent prenatal
visits because OUD in pregnancy classiﬁes as highrisk. Our secondary hypothesis was that the incidence of pregnancy complications in patients who
used OAPþ and those who used illicit or prescribed
opioids would be increased compared to the other
groups. The comparison of these incidence rates
was not statistically signiﬁcant. The small sample
size of the cohorts led to underpowered results,
from which we cannot draw any conclusions. This
was most evident in the illicit or prescribed opioids
cohort, which had the highest complication incidence (42%) and the smallest sample size where
n ¼ 12.
Our study investigated nine pregnancy complications related to gestational morbidity, which
makes it unique because no one study included all
of these complications. A multisite cohort study
showed a low incidence of placental abruption in
patients using methadone (3%), which was a similar
outcome to the MOTHER study (2.3%) and our
study (1.4%)9. In contrast, Miller et al. found that
their OAP cohort had a higher rate of placental
abruption (16%), compared to the 1% risk in the
general population10. Guan et al. investigated

complications in patients on methadone therapy;
their research showed that 1.6% of patients who
used OAP had severe maternal morbidity such as
intrapartum hemorrhage, and 5.0% had other
pregnancy complications including GDM, GH, and
pre-eclampsia/eclampsia, which are lower rates
than in our study11. A Canadian cohort study
compared pregnancy complications in patients who
used OAP, no opioids, and illicit opioids, with no
signiﬁcant difference in PPH between groups, which
as in our study PPH accounted for less than 1% of
complications in each group12.
A strength of this research is that we accounted
for illicit and recreational substances amongst those
who use OAP, which reduced confounding bias
from known pharmacological side effects. Potential
confounders we did not account for include induction length, and opioid use prior to and during
pregnancy. Due to the structure of this retrospective
cohort study and the use of patient hospital records
that were ﬁltered by ICD-10 codes, there was
inconsistent documentation of patients’ history of
opioid use, length of time of opioid use, and
whether opioids were used throughout pregnancy,
in early pregnancy, or prior to pregnancy. We were
only able to determine the medications the patients
were using at the time of delivery by viewing records from the labor and delivery unit. Many of the
speciﬁed complications have well-known risk factors; morbidly adherent placenta is a strong risk
factor for postpartum hemorrhage. While we had a

Table 4. Breakdown of pregnancy complication categories for each cohort

Placental Abruption
Placenta Accreta
Placenta Percreta
Placenta Increta
GH
Pre-Eclampsia
Eclampsia
GDM
PPH
Total Complications

OAP

OAPþ

Illicit or
Prescribed Opioids

No
Opioids

Total Complications

1
0
0
0
3
3
0
0
1
8

1
0
0
0
1
3
0
0
1
6

2
0
0
0
0
2
0
1
0
5

10
2
0
0
96
133
2
139
59
441

14
2
0
0
100
141
2
140
61
460

16 Placental Abnormalities

243 Hypertensive Disorders

201 Other Complications

Table 5. Statistical analysis comparing incidences in each cohort
Cohort Comparisons

Two-sided z-score

P-value (signiﬁcance <0.025)

OAP vs. OAPþ
OAP vs. Illicit/Prescribed Opioids
OAP vs. No Opioids
OAP þ vs. Illicit/Prescribed Opioids
OAP þ vs. No Opioids
Illicit/Prescribed Opioids vs No Opioids

0.55
1.48
2.50
0.06
1.37
1.45

0.58
0.14
0.01a
0.95
0.17
0.15

a

denotes a signiﬁcant comparison
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large overall sample size, the distribution within
each cohort was variable, which impacted the signiﬁcance of the statistical analysis. The low sample
size of the OAPþ and illicit/prescribed opioids
groups resulted in underpowered comparisons.
Other limitations include the opportunity for error
with inconsistent EMR documentation and retrieval
of data. Our study population was selected from a
single institution and geographic region, and we did
not account for other health comorbidities, race, or
socioeconomic status in our population. There were
several patients who had multiple complications in
the same pregnancy, and we accounted for each
complication separately, which could inﬂate
percentages. It is important to consider that our
ﬁndings may be due to the transfer of high-risk
patients with severe, known complications to a tertiary care center prior to delivery, however, due to
the small number of patients seen by our community hospital, our sample size would have been
further limited if we used more robust exclusion
criteria. We did not review the time of initiation or
the dose of OAP for each patient. We did not
include nicotine as a substance of interest in our
cohorts due to the inconsistency of reporting, and
we did not separate people who used other illicit
substances from the no opioids group.
Considerations for future research would be to
repeat this study with a larger population such that
we could make comparisons across multiple institutions and geographic regions. Comparing the
OAP and illicit/prescribed opioids group would
provide valuable clinical insight on the safety of
these medications during pregnancy. It would also
be important to separate people who use illicit
substances identiﬁed on urine toxicology screening
and nicotine from the no opioids group.

5. Conclusion
Pregnant patients who used OAP had a signiﬁcantly lower incidence of pregnancy complications
compared to those who used no opioids. The incidence of pregnancy complications in patients who
used OAP þ compared to illicit or prescribed opioids was not statistically signiﬁcant. The results of
this research show that there is a need for more
studies that focus on pregnancy complications that
affect the birthing person. If supported by further
research
across
multiple
institutions
and
geographical regions, the data found in this study
could aid providers in counseling their pregnant
patients on the relative safety of OAP initiation or
maintenance.
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